Navigation Links
Mimedx Scientific Study Is Electronically Published in The International Wound Journal
Date:8/1/2013

MARIETTA, Ga., Aug. 1, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Biological Properties of Dehydrated Human Amnion/Chorion Grafts: Implications for Chronic Wound Healing" has been electronically published in the International Wound Journal.  The electronic publication of the study is available at http://mimedx.com/images/pdf/Koob_IWJ_Scientific_Article_12140.pdf. The hard copy is scheduled to be published in the December 2013 edition of the International Wound Journal.

MiMedx's proprietary PURION® processed dehydrated human amnion/chorion tissue allografts (dHACM), specifically, the MiMedx EpiFix® allograft, was the subject of the study. EpiFix® was evaluated for the presence of growth factors, interleukins (ILs) and tissue inhibitors of enzymes that degrade the extracellular matrix, or metalloproteinases. Both in vitro and in vivo experiments were conducted, and it was clearly established that:

  • PURION® processed dHACM retains biologically active growth factors and regulatory factors that are at least partially responsible for its clinical effectiveness in wound healing;
  • dHACM contains one or more soluble factors that stimulate mesenchymal stem cell migration and recruitment; and
  • dHACM is a multifaceted tissue graft that has the potential to positively affect at least four distinct physiological processes:  cell proliferation, inflammation, metalloproteinase activity, and recruitment of stem cells – all of which are integral to regenerative wound healing and soft tissue repair.

"As we state
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MiMedx Announces Record Second Quarter Results
2. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
3. MiMedx To Exceed High End Of Second Quarter Guidance
4. MiMedx to Ring NASDAQ Stock Market Opening Bell
5. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
6. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
7. MiMedx Announces Record First Quarter 2013 Results
8. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
9. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
10. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
11. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 Pharmaco-Kinesis Corporation (PKC) announced today that ... Shutters on the Beach in Santa Monica, ... the Company,s innovative Metronomic Biofeedback Pump (MBP), a fully ... over time to a target site of the human ... system in real-time.  ...
(Date:5/26/2015)... , May 26, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that all ... 2014 were exercised prior to their expiry on June ... of $11.7 million. "We thank our shareholders ... President and CEO of Asterias. "This exercise of warrants ...
(Date:5/26/2015)... , May 26, 2015 US-Australian drug discovery and development ... it will present at the 2015 Marcum MicroCap Conference ... at the Grand Hyatt Hotel. The ... CEO, is scheduled to begin at 9.30 a.m. ET and will ... to http://wsw.com/webcast/marcum3/nvgn . The annual Marcum MicroCap ...
(Date:5/25/2015)... Where is the universe expanding to? ... honest answer is that nobody is entirely sure." , ... the month of June, starting with the ULI Florida ... to top tech trends. And one of the most ... universe is expanding to. According to Einstein’s theory of ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 2Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 3
... Phase 2 monotherapy trial to be initiated by end ... Biogen Idec,Inc. (Nasdaq: BIIB ) and PDL ... Phase 2 data demonstrated a significant reduction in new ... therapy in patients with active relapsing multiple,sclerosis (MS). These ...
... VAUDREUIL-DORION, QC, Oct. 11 /PRNewswire-FirstCall/ - The Board ... announce the appointment of,Mr. James A. Northrop as ... A member of the Board of Directors ... executive with a record of success in rapid ...
... ON, Oct. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... identifies, develops,and commercializes differentiated products for patients worldwide, ... take place on November,28th, 2007 at 4:00pm at ... The Exchange Tower, 130 King Street West, Toronto, ...
Cached Biology Technology:Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6Immunotec Inc. announces appointment of President & CEO James A. Northrop 2YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS 2YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS 3
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... seafood, the options are many and so are some of the ... healthy? Is it safe? Is it endangered? While there are many ... an iPhone app a group of researchers have found a ... then it is likely to be healthy to eat too," said ...
... are more common than ever before. According to the ... Americans suffers from an allergy from milder forms ... allergies which can lead to anaphylactic shock. ... an allergic reaction, the treatment is too limited, says ...
... Boulder, Colo., USA Two Geology studies focus on ... view of alpine denudation and the other studying and ... include fossil microatolls and sea level; the potential rupture ... Northwest and British Columbia; paleoclimate; and the relationship between ...
Cached Biology News:Study finds healthy seafood comes from sustainable fish 2What sets allergies in motion? 2What sets allergies in motion? 3Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 2Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 3Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 4Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 5Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 6Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 7Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 8
Antibodies were affinity purified using epitopes specific to USP33 immobilized on solid support....
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
...
...
Biology Products: